Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SkinBioTherapeutics ( (GB:SBTX) ) has issued an update.
SkinBioTherapeutics, a UK AIM-listed life science group specialising in skin health technologies and microbiome-based products, develops cosmetic skincare through its SkinBiotix platform and gut-skin axis supplements under the AxisBiotix brand. The company works with Croda on the Zenakine active ingredient and is expanding its footprint via acquisitions that add new distribution channels and manufacturing capacity.
The group has appointed beauty and wellness veteran Rachel Parsonage as interim CEO for six months, with a concurrent Board role pending standard regulatory checks. Executive chairman Martin Hunt said her turnaround and stakeholder-management experience is central to efforts to stabilise the business, support a forensic investigation into current issues and refocus SkinBioTherapeutics on restoring momentum and accelerating growth.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is driven primarily by weak financial quality (ongoing losses and negative cash flow) and a pronounced technical downtrend (price far below major moving averages, negative MACD). Strong revenue growth and a relatively conservative balance sheet provide partial support, but valuation is constrained by unprofitability and no dividend data.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life sciences company focused on skin health, built around its proprietary SkinBiotix platform developed with the University of Manchester. Its core business targets the skin healthcare market through cosmetic skincare, food supplements addressing the gut-skin axis, and related dermatological applications.
The company partners with Croda to use SkinBiotix as an active ingredient under the Zenakine name, and markets AxisBiotix food supplements for inflammatory skin conditions via direct channels, Amazon and selected Superdrug stores. SkinBioTherapeutics is also pursuing a consolidation strategy through acquisitions in complementary skincare and cosmetic areas that add distribution reach and manufacturing capabilities.
Average Trading Volume: 4,510,248
Technical Sentiment Signal: Sell
Current Market Cap: £20.73M
Find detailed analytics on SBTX stock on TipRanks’ Stock Analysis page.